Analyzing Haleon (NYSE:HLN) and Synergy CHC (NASDAQ:SNYR)

Haleon (NYSE:HLN) and Synergy CHC (NASDAQ:SNYR) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Insider and Institutional Ownership

6.7% of Haleon shares are owned by institutional investors. 32.9% of Synergy CHC shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Haleon has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Synergy CHC has a beta of -0.14, suggesting that its stock price is 114% less volatile than the S&P 500.

Profitability

This table compares Haleon and Synergy CHC’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haleon	N/A	N/A	N/A
Synergy CHC	-60.02%	N/A	-30.30%

Valuation & Earnings

This table compares Haleon and Synergy CHC”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haleon	$14.54 billion	2.94	$2.20 billion	$0.39	24.88
Synergy CHC	$30.38 million	0.05	-$12.34 million	($1.40)	-0.07

Haleon has higher revenue and earnings than Synergy CHC. Synergy CHC is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Haleon and Synergy CHC, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haleon	2	4	3	2	2.45
Synergy CHC	1	1	2	0	2.25

Synergy CHC has a consensus price target of $6.25, suggesting a potential upside of 6,168.81%. Given Synergy CHC’s higher probable upside, analysts clearly believe Synergy CHC is more favorable than Haleon.

Summary

Haleon beats Synergy CHC on 12 of the 14 factors compared between the two stocks.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

About Synergy CHC

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.